908 related articles for article (PubMed ID: 21481640)
1. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
2. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
[TBL] [Abstract][Full Text] [Related]
3. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
4. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
5. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
6. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
7. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease.
Tuszynski T; Rullmann M; Luthardt J; Butzke D; Tiepolt S; Gertz HJ; Hesse S; Seese A; Lobsien D; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1077-87. PubMed ID: 26739328
[TBL] [Abstract][Full Text] [Related]
10. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
12. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?
Catafau AM; Bullich S; Seibyl JP; Barthel H; Ghetti B; Leverenz J; Ironside JW; Schulz-Schaeffer WJ; Hoffmann A; Sabri O
J Nucl Med; 2016 Nov; 57(11):1740-1745. PubMed ID: 27363836
[TBL] [Abstract][Full Text] [Related]
13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of early-phase [
Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
[TBL] [Abstract][Full Text] [Related]
15. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.
Hamelin L; Lagarde J; Dorothée G; Leroy C; Labit M; Comley RA; de Souza LC; Corne H; Dauphinot L; Bertoux M; Dubois B; Gervais P; Colliot O; Potier MC; Bottlaender M; Sarazin M;
Brain; 2016 Apr; 139(Pt 4):1252-64. PubMed ID: 26984188
[TBL] [Abstract][Full Text] [Related]
16. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
[TBL] [Abstract][Full Text] [Related]
17. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
Villemagne VL; Ong K; Mulligan RS; Holl G; Pejoska S; Jones G; O'Keefe G; Ackerman U; Tochon-Danguy H; Chan JG; Reininger CB; Fels L; Putz B; Rohde B; Masters CL; Rowe CC
J Nucl Med; 2011 Aug; 52(8):1210-7. PubMed ID: 21764791
[TBL] [Abstract][Full Text] [Related]
18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
19. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
20. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
Barthel H; Sabri O
J Alzheimers Dis; 2011; 26 Suppl 3():117-21. PubMed ID: 21971456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
